{
     "PMID": "15555642",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20050125",
     "LR": "20131121",
     "IS": "0028-3908 (Print) 0028-3908 (Linking)",
     "VI": "47",
     "IP": "7",
     "DP": "2004 Dec",
     "TI": "Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance.",
     "PG": "1081-92",
     "AB": "An essential element of the signalling cascade leading to synaptic plasticity is the intracellular second messenger molecule guanosine 3',5'-cyclic monophosphate (cGMP). Using the novel, potent, and selective inhibitor Bay 60-7550, we show that the enzyme 3',5'-cyclic nucleotide phosphodiesterase type 2 (PDE2) is responsible for the degradation of newly synthesized cGMP in cultured neurons and hippocampal slices. Inhibition of PDE2 enhanced long-term potentiation of synaptic transmission without altering basal synaptic transmission. Inhibition of PDE2 also improved the performance of rats in social and object recognition memory tasks, and reversed MK801-induced deficits in spontaneous alternation in mice in a T-maze. Our data provide strong evidence that inhibition of PDE2 can improve memory functions by enhancing neuronal plasticity.",
     "FAU": [
          "Boess, Frank G",
          "Hendrix, Martin",
          "van der Staay, Franz-Josef",
          "Erb, Christina",
          "Schreiber, Rudy",
          "van Staveren, Wilma",
          "de Vente, Jan",
          "Prickaerts, Jos",
          "Blokland, Arjan",
          "Koenig, Gerhard"
     ],
     "AU": [
          "Boess FG",
          "Hendrix M",
          "van der Staay FJ",
          "Erb C",
          "Schreiber R",
          "van Staveren W",
          "de Vente J",
          "Prickaerts J",
          "Blokland A",
          "Koenig G"
     ],
     "AD": "Bayer Healthcare AG, Pharma Research CNS, 42096 Wuppertal-Elberfeld, Germany.",
     "LA": [
          "eng"
     ],
     "PT": [
          "Journal Article"
     ],
     "PL": "England",
     "TA": "Neuropharmacology",
     "JT": "Neuropharmacology",
     "JID": "0236217",
     "RN": [
          "0 (Phosphodiesterase Inhibitors)",
          "0 (Recombinant Proteins)",
          "E0399OZS9N (Cyclic AMP)",
          "EC 3.1.- (Exonucleases)",
          "EC 3.1.16.1 (spleen exonuclease)",
          "H2D2X058MU (Cyclic GMP)"
     ],
     "SB": "IM",
     "MH": [
          "Animals",
          "CHO Cells",
          "Cattle",
          "Cricetinae",
          "Cyclic AMP/metabolism",
          "Cyclic GMP/*metabolism",
          "Exonucleases/*antagonists & inhibitors",
          "Guinea Pigs",
          "Hippocampus/cytology/drug effects/metabolism",
          "Humans",
          "Immunohistochemistry",
          "Long-Term Potentiation/drug effects",
          "Male",
          "Maze Learning/drug effects",
          "Memory/*drug effects",
          "Mice",
          "Mice, Inbred C57BL",
          "Neuronal Plasticity/*drug effects",
          "Neurons/drug effects/*metabolism",
          "Phosphodiesterase Inhibitors/*pharmacology",
          "Psychomotor Performance/*drug effects",
          "Rats",
          "Rats, Wistar",
          "Recombinant Proteins",
          "Signal Transduction/drug effects"
     ],
     "EDAT": "2004/11/24 09:00",
     "MHDA": "2005/01/26 09:00",
     "CRDT": [
          "2004/11/24 09:00"
     ],
     "PHST": [
          "2004/03/23 00:00 [received]",
          "2004/06/02 00:00 [revised]",
          "2004/07/28 00:00 [accepted]",
          "2004/11/24 09:00 [pubmed]",
          "2005/01/26 09:00 [medline]",
          "2004/11/24 09:00 [entrez]"
     ],
     "AID": [
          "S002839080400228X [pii]",
          "10.1016/j.neuropharm.2004.07.040 [doi]"
     ],
     "PST": "ppublish",
     "SO": "Neuropharmacology. 2004 Dec;47(7):1081-92. doi: 10.1016/j.neuropharm.2004.07.040.",
     "term": "hippocampus"
}